Brought to you by 
Astellas to sell Eligard in select countries for Tolmar
29 Jan 2021
Executive Summary
Astellas Pharma Europe Ltd. has licensed rights to sell drug manufacturing company Tolmar Holding Inc.’s Eligard (leuprolide) for prostate cancer in various Asian, Middle Eastern, North African, and CIS countries. Astellas’ Asian rights include China, Taiwan, Thailand, Hong Kong, the Philippines, and Indonesia.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas to sell Eligard in select countries for Tolmar
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice